We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stratagene Highlights Results of FDA's MicroArray Quality Control Project

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stratagene Highlights Results of FDA's MicroArray Quality Control Project"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Stratagene Corporation has highlighted the U.S. Food and Drug Administration's (FDA) publication of results from its MicroArray Quality Control (MAQC) project.

As part of the FDA's Critical Path Initiative, the MAQC project aimed to develop standards and quality measures for the microarray community, so that microarrays, as a core technology of pharmacogenomics and toxicogenomics, could be used in clinical practice and regulatory decision-making.

As a result, the MAQC project will help improve microarray technology and foster its proper applications in the discovery, development and review of FDA regulated products.

"We are proud to have been a part of this collaboration that brought together a broad range of academic, governmental, and commercial organizations, all with the future of microarray technology in mind," said Joseph A. Sorge, MD, President and CEO of Stratagene.

"Stratagene's Universal Reference RNA was one of two high-quality reference standards selected as part of the MAQC project."

"These reference RNAs allow laboratories with many different microarray platforms to compare and share data in the global microarray community."